Eletriptan (Relpax) vs Meloxicam/Rizatriptan (Symbravo)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Migraine

Shared mechanism: 5-HT1B/1D receptor · full Migraine pipeline

Eletriptan (Relpax)

Marketed by Viatris

Approved in Migrainesmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Meloxicam/Rizatriptan (Symbravo)

Marketed by Axsome Therapeutics

Approved in Migrainesmall molecule
Reliable signal

NCT03896009 · Phase 3 · completed

The trial was a large, randomized, double-blind, placebo- and active-controlled study with 1,594 participants. Both prespecified primary clinical endpoints were statistically significant in favor of the meloxicam/rizatriptan combination versus placebo: 2-hour headache pain freedom and absence of the most bothersome symptom.

Reported efficacy

Long-term Safety of Chronic Intermittent Use of AXS-07 (Up to 12 months): Long-term Safety of Chronic Intermittent Use of AXS-07 (Up to 12 months): AXS-07 — Subjects with any TEAEs: 293 Participants; Subjects with suspected to be drug-related TEAEs: 118 Participants; Subjects with serious TEAEs: 8 Participants; Subjects with TEAEs that led to drug withdrawal: 10 Participants; Subjects with TEAEs that led to withdrawal from study: 13 Participants; Subjects with TEAEs that resulted in death: 0 Participants (not_applicable)

Result source: NCT04068051

Results for Migraine

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Eletriptan (Relpax): no structured comparison results are available for Migraine.

Meloxicam/Rizatriptan (Symbravo): registry results are on file for Migraine, but their comparison mappings are not yet available.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Eletriptan (Relpax)'s landscape · Meloxicam/Rizatriptan (Symbravo)'s landscape